AAN 2021 | Comprehensive migraine update at AAN 2021
Jessica Ailani, MD, FAAN, Medstar Georgetown University Hospital, Washington, DC, shares an overview of the topics discussed in the ‘Comprehensive migraine update’ session at the AAN 2021 virtual annual meeting. The case-based session reviewed updates in migraine treatment that have occurred over the last 3 years. Key topics included how to diagnose patients effectively and quickly, optimal treatment approaches, where newer treatment options should fit in the migraine treatment paradigm, and the importance of shared decision making. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.
Disclosures
Consulting: (Honoraria for independent consulting) Amgen, Abbvie, Biohaven, Eli Lilly and Company, Lundbeck, Teva, Impel, Satsuma, Theranica, Axsome, Neso, GlaxoSmithKline, Aeon, Medscape
Ownership of Stocks: CtrM
Speakers Bureau: (Honoraria for promotional speaking) Allergan/Abbvie, Amgen, Biohaven, Eli Lilly and Company, Lundbeck, Teva
Editorial services: (Honoraria) Current Pain and Headache Reports, Section editor, Unusual Headache Syndromes, NeurologyLive, SELF (medical reviewer)
Clinical Trial Grants: (Fees to Institution) American Migraine Foundation, Allergan, Biohaven, Eli Lilly and Company, Satsuma, Zosano
